Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05320887
Other study ID # IRB00080010
Secondary ID 5U54DA031659-09
Status Completed
Phase N/A
First received
Last updated
Start date July 27, 2022
Est. completion date August 6, 2023

Study information

Verified date March 2023
Source Wake Forest University Health Sciences
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This study is proposing a four condition Electronic Tobacco Marketplace (ETM) study to determine if banning normal nicotine content (NNC) is sufficient for encouraging smokers to switch to potentially less harmful products or if the availability of higher nicotine and/or flavored alternative products (specifically e-cigarettes) are needed to achieve maximal reductions in smoking.


Description:

The Family Smoking Prevention and Tobacco Control Act (FSPTCA) passed in 2009 provides the FDA with the authority to regulate tobacco products. One provision in this legislative act empowers the FDA to set limits on constituents in tobacco products, including nicotine. Such a measure has the potential to reduce the chance of individuals experimenting with smoking from becoming dependent and enable current smokers to quit when they are motivated to do so. Although the proposal to reduce nicotine in cigarettes has been met with skepticism by some because of concerns over compensatory smoking behavior and the potential emergence of a black market, this policy measure was considered to be technically feasible by the American Medical Association and the British Medical, by tobacco control researchers, policymakers and governmental officials who were convened in a meeting on nicotine regulation8, and by the World Health Organization Study Group on Tobacco Product Regulation. Most importantly, in July 2017, FDA Commissioner Gottlieb announced he was "directing our Center for Tobacco Products to develop a comprehensive nicotine regulatory plan premised on the need to confront and alter cigarette addiction." This announcement was followed on March 16, 2018 by the release of the Advance Notice of Proposed Rulemaking entitled "Tobacco Product Standard for Nicotine Level of Combusted Cigarettes" (ID: FDA-2017-N-6189-0001) "to obtain information for consideration in developing a tobacco product standard to set the maximum nicotine level for cigarettes." This study proposes to conduct a within-subjects, multi-session virtual lab study and validation field assessment to determine how the availability of flavored e-liquids affects product purchasing among cigarette smokers. Adult daily cigarette smokers (N=64) will be recruited for this study. After initial eligibility is assessed, participants will complete six virtual sessions (1 baseline, 4 experimental, and 1 follow-up) and one field assessment to evaluate their tobacco use.


Recruitment information / eligibility

Status Completed
Enrollment 64
Est. completion date August 6, 2023
Est. primary completion date July 31, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 21 Years and older
Eligibility Inclusion Criteria: - 21+ years of age - Self-report smoking at least 5 cigarettes per day for the past year - Breathe carbon monoxide (CO) level > 8 ppm or positive urine NicCheck - Willingness to use other tobacco products during the study - Speak, comprehend, and read English sufficiently to complete study procedures - Have home access to a computer, smart phone, or tablet with a web camera and internet access - Tried a vaping device at least once in their lifetime Exclusion Criteria: - Currently seeking treatment to quit smoking - Self-reported serious medical or psychiatric condition(s) including cardiovascular and chronic respiratory diseases - Body temperature > 100.4 F - Cold, flu or COVID-19 symptoms including fever, cough, and runny nose in the past 30 days - Currently pregnant, breastfeeding or intending to become pregnant for the duration of the study or unwilling to agree to use adequate protection to avoid pregnancy - CO reading > 80 ppm

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Normal Nicotine Content Vape with all flavor e-liquids
Participants are randomly assigned to the order of each marketplace Group
Normal nicotine content vape with tobacco e-liquids
Participants are randomly assigned to the order of each marketplace Group
Low nicotine content vape with all flavor e-liquids
Participants are randomly assigned to the order of each marketplace Group
Low nicotine content vape with tobacco e-liquids
Participants are randomly assigned to the order of each marketplace Group

Locations

Country Name City State
United States Wake Forest University Health Sciences Winston-Salem North Carolina

Sponsors (3)

Lead Sponsor Collaborator
Wake Forest University Health Sciences National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

References & Publications (8)

Hatsukami DK, Perkins KA, Lesage MG, Ashley DL, Henningfield JE, Benowitz NL, Backinger CL, Zeller M. Nicotine reduction revisited: science and future directions. Tob Control. 2010 Oct;19(5):e1-10. doi: 10.1136/tc.2009.035584. — View Citation

Henningfield JE, Benowitz NL, Slade J, Houston TP, Davis RM, Deitchman SD. Reducing the addictiveness of cigarettes. Council on Scientific Affairs, American Medical Association. Tob Control. 1998 Autumn;7(3):281-93. doi: 10.1136/tc.7.3.281. — View Citation

Jarvis MJ, Bates C. Eliminating nicotine in cigarettes. Tob Control. 1999 Spring;8(1):106-7; author reply 107-9. No abstract available. — View Citation

Kozlowski LT. Cigarette prohibition and the need for more prior testing of the WHO TobReg's global nicotine-reduction strategy. Tob Control. 2017 Mar;26(e1):e31-e34. doi: 10.1136/tobaccocontrol-2016-052995. Epub 2016 Jun 29. No abstract available. — View Citation

Kozlowski LT. Let actual markets help assess the worth of optional very-low-nicotine cigarettes before deciding on mandatory regulations. Addiction. 2017 Jan;112(1):3-5. doi: 10.1111/add.13515. Epub 2016 Aug 23. No abstract available. — View Citation

Kozlowski LT. Prospects for a nicotine-reduction strategy in the cigarette endgame: Alternative tobacco harm reduction scenarios. Int J Drug Policy. 2015 Jun;26(6):543-7. doi: 10.1016/j.drugpo.2015.02.001. Epub 2015 Feb 23. — View Citation

Shatenstein S. Eliminating nicotine in cigarettes. Tob Control. 1999 Spring;8(1):106; author reply 107-9. No abstract available. — View Citation

World Health Organization. WHO STUDY GROUP ON TOBACCO PRODUCT REGULATION. Report on the Scientific Basis of Tobacco Product Regulations: Fifth Report of a WHO Study Group. World Health Organ Tech Rep Ser. 2015;(989):1-234, back cover. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Product use themes emerging from the qualitative interviews Participants are asked about their opinions and experiences using tobacco products other than their usual brand during the field assessment. 1 year
Other Tobacco Product use during Field Assessment Participants are asked what products they had used and quantity every day during the field assessment. 1 year
Other Biomarkers of exposure during Field Assessment - Carbon Monoxide Product use and biomarkers of exposure during the field assessment will be analyzed using linear regression or other appropriate regression models. The model for primary analysis of these data will include main effects for each of the two factors (for the ETM condition carried into the field assessment), and the corresponding baseline measure to improve precision. Carbon Monoxide (CO) is collected in ppm. 1 year
Other Biomarkers of exposure during Field Assessment - Cotinine Product use and biomarkers of exposure during the field assessment will be analyzed using linear regression or other appropriate regression models. The model for primary analysis of these data will include main effects for each of the two factors (for the ETM condition carried into the field assessment), and the corresponding baseline measure to improve precision. Cotinine is collected in ng/ml. 1 year
Primary Number of cigarettes purchased Number of cigarettes purchased (analyzed as raw data and using derived behavioral economic measures) 1 year
Secondary Amount of E-liquid purchased E-liquid purchased (analyzed as raw data and using derived behavioral economic measures) 1 year
Secondary Proportion of Participants completing Flavor and Nicotine Content Discrete Choice Projections The proportion of participants projected to choose a cigarette over an e-cigarette under different potential regulatory scenarios, as determined by logistic regression 1 year
Secondary Perceived Health Risk Scale Scores Perceived Health Risk Scale - The response options rely on a 5-point Likert-like scale: 0=no risk; 1=low risk; 2=moderate risk; 3=high risk; 4=very high risk 1 year
Secondary Product Evaluation Scale Scores Product Evaluation Scale - which measures responses to cigarettes (e.g., reward, satisfaction) - The response options rely on a 7-point Likert-like scale: 1=not at all; 2= very little; 3= a little; 4= moderately; 5= a lot; 6= quite a lot; 7= extremely 1 year
Secondary Minnesota Nicotine Withdrawal Scale Scores Minnesota Nicotine Withdrawal Scale - a measure of nicotine withdrawal symptoms. The response options rely on a 5-point Likert-like scale; 0=None; 1= Slight; 2=Mild; 3=Moderate; 4=Severe 1 year
Secondary Questionnaire on Smoking Urges Score Questionnaire on Smoking Urges - measures the urge to smoke. The response options rely on a 7-point Likert-like scale: 1=Strongly Disagree; 2; 3; 4; 5; 6; 7= Strongly Agree 1 year
Secondary Tobacco Product Interest Scores Tobacco Product Interest of different products; Slider scale ranging from 0=No Interest to 100=Very Interested 1 year
Secondary Tobacco Policy Questionnaire Scores Tobacco Policy Questionnaire scored from Support, Oppose, and Don't know for personal opinions on relevant Tobacco Policies 1 year
See also
  Status Clinical Trial Phase
Completed NCT04043728 - Addressing Psychological Risk Factors Underlying Smoking Persistence in COPD Patients: The Fresh Start Study N/A
Recruiting NCT06033599 - Motivational Interviewing and Mindfulness-Oriented Recovery Enhancement Phase 3
Enrolling by invitation NCT05415371 - Persistent Poverty Counties Pregnant Women With Medicaid N/A
Completed NCT04284813 - Families With Substance Use and Psychosis: A Pilot Study N/A
Completed NCT06105424 - BRP1602: Evaluation of Technical and Logistical Feasibility to Measure Lung Permeability N/A
Completed NCT01311830 - Enhancing Smoker Utilization of the Minnesota Quitline Through Support Persons N/A
Completed NCT04566198 - Smoking in the Paris Fire Brigade and Comparison According to the Type of Service (Permanent or On-call)
Completed NCT04107779 - Changes in Biomarkers of Cigarette Smoke Exposure After Switching Either Exclusively or Partly to JUUL ENDS N/A
Completed NCT05092919 - The Effect of Sweet Flavoring on the Rewarding and Reinforcing Value of Cigarillo Use Among Young Adults Early Phase 1
Terminated NCT05274217 - Journey of Transformation Curriculum for Native American Adolescents N/A
Enrolling by invitation NCT06042361 - Enhancing Equity in Smoke-free Housing N/A
Completed NCT03235713 - EMA for Tobacco Control Policy Research
Withdrawn NCT03352635 - Mechanisms of Ethnic/Racial Differences in Lung Cancer Due to Cigarette Smoking Clinical and Biomarkers Core N/A
Completed NCT03151421 - Air Quality Feedback to Reduce Second-hand Smoke (SHS) Exposure in the Home N/A
Completed NCT03446170 - Effect of Cigarette Pack Warnings and Packaging Among Young Adult Smokers N/A
Completed NCT04104152 - CSD190203: A Study to Determine Subject Puffing Patterns of an Electronic Nicotine Delivery System in an Ambulatory Setting N/A
Not yet recruiting NCT05999383 - Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration Phase 2
Recruiting NCT04429568 - THC Crossover Study N/A
Completed NCT04632030 - Shrinking the Size of the Tobacco Power Wall N/A
Completed NCT04094363 - CSD190202: Study to Assess Elements of Abuse Liability for Two Electronic Nicotine Delivery Systems N/A